Expanded Access to Navitoclax

AbbVie

Status

Conditions: Myelofibrosis; Lymphoblastic Lymphoma; Acute Lymphocytic Leukemia (ALL)

Treatments: Drug: Venetoclax; Drug: Navitoclax

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT03592576

C19-199

C19-922 (Other Grant/Funding Number)

Details and patient eligibility

About

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to navitoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Sex

Ages: 4+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria